Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 286,210 |
|
|||||
| News | - | ||||||
| Day High | 23.31 | Low High |
|||||
| Day Low | 22.18 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Enliven Therapeutics Inc | ELVN | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.09 | 0.39% | 22.98 | 16:02:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 22.93 | 22.18 | 23.31 | 22.98 | 22.89 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 3,425 | 286,210 | $ 22.94 | $ 6,566,425 | - | 9.80 - 26.00 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:07:28 | 49 | $ 22.98 | USD |
Enliven Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 261.32M | 41.35M | - | 0 | -71.58M | -1.73 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Enliven Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ELVN Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 23.85 | 24.20 | 22.18 | 23.41 | 493,191 | -0.87 | -3.65% |
| 1 Month | 16.65 | 25.155 | 16.16 | 22.01 | 399,023 | 6.33 | 38.02% |
| 3 Months | 17.29 | 26.00 | 10.9001 | 20.40 | 350,571 | 5.69 | 32.91% |
| 6 Months | 11.40 | 26.00 | 9.80 | 18.21 | 247,544 | 11.58 | 101.58% |
| 1 Year | 21.48 | 26.00 | 9.80 | 18.16 | 201,776 | 1.50 | 6.98% |
| 3 Years | 24.20 | 26.00 | 9.80 | 18.52 | 187,422 | -1.22 | -5.04% |
| 5 Years | 24.20 | 26.00 | 9.80 | 18.52 | 187,422 | -1.22 | -5.04% |
Enliven Therapeutics Description
| Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule inhibitors to help patients with cancer. The Company focuses on addressing existing and emerging unmet needs with a precision oncology approach. The Company is advancing two parallel lead product candidates, ELVN-001 and ELVN-002, as well as pursuing several additional research stage opportunities. Its first product candidate, ELVN-001, is a potent, highly selective, small molecule kinase inhibitor designed to specifically target the breakpoint cluster region-Abelson (BCR-ABL) gene fusion, the oncogenic driver for patients with chronic myeloid leukemia (CML). Its second product candidate, ELVN-002, is a potent, selective, and irreversible human epidermal growth factor receptor 2 (HER2) inhibitor with activity against various HER2 mutations, including Exon 20 insertion mutations (E20IMs) in non-small cell lung cancer (NSCLC). |
